ITCI - Intra-Cellular Therapies, Inc.

QQQ $ 629.10 $ 3.02 (0.48 %)

DIA $ 475.66 $ 0.66 (0.14 %)

SPY $ 681.92 $ 2.23 (0.33 %)

TLT $ 90.32 $ -0.27 (-0.3 %)

GLD $ 368.13 $ -2.01 (-0.54 %)

Previous Close

$ 131.87

Open

Bid

-- x --

Ask

-- x --

Day's Range

-- - --

52 Week Range

$ 64.09 - $ 131.98

Volume

16,062,974

Average Volume

Market Cap

14.02B

Beta (5Y Monthly)

$ 0.57

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	02-21-2025	12-31-2024	10-K
2	10-30-2024	09-30-2024	10-Q
3	08-07-2024	06-30-2024	10-Q
4	05-07-2024	03-31-2024	10-Q
5	02-22-2024	12-31-2023	10-K
6	11-02-2023	09-30-2023	10-Q
7	08-03-2023	06-30-2023	10-Q
8	05-04-2023	03-31-2023	10-Q
9	03-01-2023	12-31-2022	10-K
10	11-03-2022	09-30-2022	10-Q
11	08-09-2022	06-30-2022	10-Q
12	05-10-2022	03-31-2022	10-Q
13	03-01-2022	12-31-2021	10-K
14	11-09-2021	09-30-2021	10-Q
15	08-09-2021	06-30-2021	10-Q
16	05-10-2021	03-31-2021	10-Q
17	02-25-2021	12-31-2020	10-K
18	11-09-2020	09-30-2020	10-Q
19	08-10-2020	06-30-2020	10-Q
20	05-07-2020	03-31-2020	10-Q
21	03-02-2020	12-31-2019	10-K
22	11-05-2019	09-30-2019	10-Q
23	08-07-2019	06-30-2019	10-Q
24	05-08-2019	03-31-2019	10-Q
25	02-27-2019	12-31-2018	10-K
26	11-07-2018	09-30-2018	10-Q
27	08-02-2018	06-30-2018	10-Q
28	05-03-2018	03-31-2018	10-Q
29	03-01-2018	12-31-2017	10-K
30	11-08-2017	09-30-2017	10-Q
31	08-09-2017	06-30-2017	10-Q
32	05-10-2017	03-31-2017	10-Q
33	03-01-2017	12-31-2016	10-K
34	11-09-2016	09-30-2016	10-Q
35	08-04-2016	06-30-2016	10-Q
36	04-28-2016	03-31-2016	10-Q
37	04-28-2016	03-31-2016	10-Q
38	02-25-2016	12-31-2015	10-K
39	11-05-2015	09-30-2015	10-Q
40	08-05-2015	06-30-2015	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

Demystifying Intra-Cellular Therapies: Ins...
04/02/2025 22:01:00

stock-of-the-day-will-johnson--johnson-rally-the-sell-off-may-have-ended

Stock Of The Day: Will Johnson & Johnson R...
04/02/2025 16:26:56

Shares of Johnson & Johnson (JNJ) sold off on news regarding a dilution of its earnings. The selloff ended when it reach su...

Cantor Fitzgerald Reiterates Neutral on In...
04/02/2025 14:32:59

Cantor Fitzgerald analyst Charles Duncan reiterates Intra-Cellular Therapies (NASDAQ:ITCI) with a Neutral and maintains $132...

johnson--johnson-stops-late-stage-depression-study-over-insufficient-efficacy

Johnson & Johnson Stops Late-Stage Depress...
03/07/2025 14:03:50

Johnson & Johnson discontinues aticaprant's Phase 3 trial but explores future options. Another depression drug Spravato...

nike-to-rally-over-50-here-are-10-top-analyst-forecasts-for-monday

Nike To Rally Over 50%? Here Are 10 Top An...
02/24/2025 18:38:02

this-conagra-brands-analyst-is-no-longer-bullish-here-are-top-5-downgrades-for-monday

This Conagra Brands Analyst Is No Longer B...
02/24/2025 18:21:09

Mizuho Downgrades Intra-Cellular Therapies...
02/24/2025 13:01:18

Mizuho analyst Graig Suvannavejh downgrades Intra-Cellular Therapies (NASDAQ:ITCI) from Outperform to Neutral and lowers the...

Intra-Cellular Therapies Stock: A Deep Div...
02/21/2025 22:01:09

Needham Reiterates Hold on Intra-Cellular ...
02/21/2025 18:24:45

Needham analyst Ami Fadia reiterates Intra-Cellular Therapies (NASDAQ:ITCI) from Hold to Hold.

Intra-Cellular Therapies Q4 EPS $(0.16) Mi...
02/21/2025 13:39:11

Intra-Cellular Therapies (NASDAQ:ITCI) reported quarterly losses of $(0.16) per share which missed the analyst consensus estima...

axsomes-axs-05-in-alzheimers-agitation-could-be-billion-dollar-opportunity-says-analyst

Axsome's AXS-05 In Alzheimer's Agitation C...
02/18/2025 17:25:15

Axsome Therapeutics reports strong Q4 2024 revenues, driven by increased sales of Auvelity and Sunosi. Anticipated milestones a...

Canaccord Genuity Downgrades Intra-Cellula...
01/31/2025 10:23:45

Canaccord Genuity analyst Sumant Kulkarni downgrades Intra-Cellular Therapies (NASDAQ:ITCI) from Buy to Hold and raises the ...

Demystifying Intra-Cellular Therapies: Ins...
01/22/2025 21:00:19

RBC Capital Downgrades Intra-Cellular Ther...
01/22/2025 17:07:09

RBC Capital analyst Brian Abrahams downgrades Intra-Cellular Therapies (NASDAQ:ITCI) from Outperform to Sector Perform and r...

Johnson & Johnson Q4 Earnings: Cancer Drug...
01/22/2025 13:21:09

Johnson & Johnson's Q4 sales hit $22.52 billion, with strong growth in MedTech and oncology. 2025 guidance shows promis...

top-4-health-care-stocks-you-may-want-to-dump-in-q1

Top 4 Health Care Stocks You May Want To D...
01/21/2025 11:06:49

microstrategy-sofi-technologies-and-carvana-are-among-top-large-cap-gainers-last-week-jan-13-jan-17-are-the-others-in-your-portfolio

MicroStrategy, SoFi Technologies And Carva...
01/19/2025 13:33:26

These 11 large-cap stocks saw significant growth last week, with notable news from companies such as Johnson & Johnson, Mic...

Piper Sandler Downgrades Intra-Cellular Th...
01/14/2025 16:37:38

Piper Sandler analyst David Amsellem downgrades Intra-Cellular Therapies (NASDAQ:ITCI) from Overweight to Neutral and raises...

12-health-care-stocks-moving-in-mondays-pre-market-session

12 Health Care Stocks Moving In Monday's P...
01/13/2025 21:05:39

intra-cellular-therapies-stock-is-surging-monday-whats-going-on

Intra-Cellular Therapies Stock Is Surging ...
01/13/2025 19:58:11

Shares of Intra-Cellular Therapies Inc. (NASDAQ: ITCI) are trading higher Monday after Johnson & Johnson agreed to acquire ...